Cancer Immunology Group
led by Dr. Eyad Elkord
Dr Elkord’s research group focuses on investigating mechanisms employed by tumors to evade immune-mediated destruction at both the cellular and molecular levels with special interest in the role and function of immunosuppressive cells.
More specifically our group is interested in:
Immune checkpoints and their ligands.
- Investigating the mechanisms employed by tumors to evade immune-mediated destruction with special interest in the role and function of immunosuppressive cells [T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs)] in cancer;
- Molecular and epigenetic profiling of tumor tissues and tumor-infiltrating immune cells in breast and colorectal cancers;
- Investigating the role of immune checkpoints in T cells as potential therapeutic targets;
- Interaction and mechanisms utilized by tumors to induce and/or expand immunosuppressive cells (Tregs and MDSCs);
- Investigating potential and novel markers for discriminating the different Treg subsets including thymic and peripherally induced Tregs;
- Differential characterization of T regulatory cells in cancer patients compared to healthy individuals in cancer;
- Analyzing the cellular immunity to human tumor-associated antigens and discovering MHC class I and II epitopes derived from these antigens;
- Investigating the mechanism of action of some anti-cancer therapies.
Various immune checkpoint molecules expressed on Tregs and/or effector T cells are shown with their ligands. Immune checkpoints such as CTLA-4, PD-1, TIGIT, LAG-3 and TIM-3 expressed on Tregs and/or T effector cells bind with their respective ligands on antigen-presenting cells and/or tumor cells, which assists in evasion of anti-tumor immune responses.
Dr. Eyad Elkord's Group